UNSPSC 51111834: Bazedoxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C30H34N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q16TT9C5BK, chemically known as 1h-indol-5-ol, 1-((4-(2-(hexahydro-1h-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl- but generally known as bazedoxifene, which bears US NIH Compound Identifier 154257. Bazedoxifene most often comes in basic and acetate forms.

UNSPSC 51111834 Bazedoxifene, a Commodity code, covers osteoporosis and hormone-replacement pharmaceuticals that state and local governments procure through cooperative purchasing agreements and multistate pharmaceutical contracts. Based on recent solicitations, state and local buyers source bazedoxifene and related generic multi-source pharmaceuticals through established distribution networks, typically bundled with over-the-counter products and other therapeutic agents in volume purchasing arrangements that emphasize price competitiveness, supply chain compliance, and manufacturer pricing flexibility. The issuing bodies include state procurement offices administering cooperative purchasing alliances as well as the state and local government facilities—including corrections, health departments, and municipal health clinics—that draw on these contracts as end users. Manufacturers and authorized distributors respond to these solicitations rather than individual healthcare providers, reflecting the consolidated, institutional-scale buying pattern characteristic of state-level pharmaceutical procurement.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act; evaluation weighs price competitiveness at 75 percent, with remaining points distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new responders through June 30, 2028, with performance penalties ranging from $200 to $1,500 per violation for reporting delays, missed onboarding, or improper class-of-trade denials. Submissions closed March 26, 2026, with questions due February 18, 2026, and awarded vendors providing product availability by May 15, 2026 with agreements effective July 1, 2026.